Aptose Biosciences (TSE:APS) Sets New 12-Month Low - Here's What Happened

Key Points

• Aptose Biosciences shares reached a new **52-week low** of **C$1.72** during trading, down from the previous close of **C$2.05**.
• The company's **debt-to-equity ratio** stands at **-117.37**, indicating significant financial challenges, alongside a **PE ratio** of **-0.35**.
• Aptose is a **clinical-stage biotechnology** firm focused on developing personalized cancer therapies, with its lead program being **APTO-253**, currently in Phase I trials.

Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO shares reached a new 52-week low during trading on Wednesday . The stock traded as low as C$1.72 and last traded at C$1.72, with a volume of 16190 shares. The stock had previously closed at C$2.05.

Aptose Biosciences Price Performance

The firm has a fifty day simple moving average of C$1.97 and a 200 day simple moving average of C$3.95. The company has a market capitalization of C$72.34 million, a PE ratio of -0.33 and a beta of 1.36. The company has a debt-to-equity ratio of -117.37, a quick ratio of 5.41 and a current ratio of 1.05.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.